Industrial Sector

CellCarta offers its pharmaceutical partners worldwide a wide range of services to support the development of therapeutic modalities, biomarkers and companion diagnostic tests, covering both preclinical and clinical stages.
For example, in support of the clinical development of RNA vaccines, CellCarta leverages its multiple state-of-the-art technology platforms, including flow cytometry and ELISpot for immune response monitoring, and its genomics and histopathology platforms for quantifying cellular responses in tissues. In addition, by combining its platforms, CellCarta offers cutting-edge services in spatial transcriptomics and single-cell analysis, providing comprehensive support for your bioanalysis projects.

CQIB is a life sciences incubator/accelerator offering laboratories and workspaces for start-up companies. Incubated companies benefit from over $5 million worth of scientific equipment, most of which is dedicated to DNA and RNA analysis.

CQIB is currently home to teams working on RNA therapeutics and adjuvant production.

Epitopea is a transatlantic cancer immunotherapy company founded in 2021 between Cambridge (UK), and Montreal (CA). This company originate from Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer of the Université de Montréal. Epitopea is developing ready-to-use RNA-based immunotherapies for the treatment of difficult-to-cure cancers, by targeting a new class of antigens which had previously been unexploited and are widely shared by patients with the same type of tumor.

The company has discovered using its proprietary CryptoMapTM platform a vast library of novel antigens (TSA CryptigenTM), which draws on immunopetidomics, genomics and a bioinformatics pipeline to identify aberrantly expressed tumor-specific antigens (aeTSA).
Epitopea is backed by leading transatlantic life sciences investors, including Advent Life Sciences, CTI Life Sciences, Cambridge Innovation Capital, Fonds de Solidarité FTQ, Harrington Discovery Institute, Novateur Ventures and Investissement Québec. The company has raised over US$13 million.

Feldan is a biopharmaceutical company specializing in the development of treatments based on the intracellular delivery of therapeutic products. Feldan has developed the Feldan Shuttle, an exclusive peptide-based technology that enables the safe and effective delivery of various compounds inside cells.

This technology paves the way for the development of a new generation of treatments by providing access to intracellular components beyond the reach of existing drugs. Feldan’s pipeline focuses on skin and lung diseases, and is based on the intracellular delivery of PMO (Phosphorodiamidate morpholino oligomers) RNA technologies.

Galenvs is a specialized precision developer & manufacturer of DNA/RNA oligonucleotides for therapeutics, offering services from proof-of-concept through in vitro validation and pilot-scale production.

This includes ASO, SSO, PMO, siRNA, sgRNA design and synthesis – as well as chemical modifications for enhanced stability and cellular uptake.

Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone.

By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases.

Molecular Forecaster combines world-class computational tools with deep domain expertise to tackle the toughest challenges in early-stage drug discovery.

We develop and apply software to design small molecules to interact with RNA.

Nanofacile Inc. accelerates and reduces the risks associated with R&D of lipid nanoparticle-based gene therapies with advanced, easy-to-use technology. Our technology is a complete solution including encapsulation recipes and an advanced microfluidic device.

This approach simplifies preclinical development, making it faster and more accessible. We are currently actively developing this technology and seeking partnerships to improve and extend our offering.

Neopharm Life Sciences, offers a comprehensive suite of RNA analysis services tailored to meet the changing needs of the biotechnology and life sciences industries. Services are designed to support researchers, pharmaceutical and biotech companies at every stage of the product development lifecycle, from early discovery to commercial launch and beyond.

– RNA analysis services
– Identity confirmation
– Impurity detection
– Specialized ASO RNA analysis

NMX, a contract research partner, supports drug discovery targeting biological macromolecules of therapeutic interest, including RNA. To achieve this, NMX is able to produce these macromolecules (in vitro transcription for RNA), purify them by chromatography and then screen a library of small molecules to identify potential ligands.

The interaction is then characterized by a variety of biophysical methods, including NMR, ITC, MST and DSF, in order to select the molecules offering the best potential for the desired modulation of the biological effect associated with the macromolecule.

Polaris Oligonucleotides is a Canadian-based biopharma services provider dedicated to advancing oligonucleotides science by leveraging cutting-edge synthetic chemistry. Our service offer spans all types of synthetic oligonucleotides, and we specialize in highly modified or synthetically challenging sequences. We offer a broad inventory of off-the-shelf modifications and can design and produce custom modifications for specialty applications.

Our team of highly skilled chemists and chemical biologists can handle all typical therapeutic oligonucleotide modalities (siRNA, ASO, PMO), as well as post-synthetic functionalization with molecular effectors for a wide range of applications (fluorescent probes and quenchers, affinity capture tags, cell-penetrating peptides), and we adhere to the highest standards of quality.

Providence Therapeutics is an mRNA Medicines Platform company with over nine years of expertise in the mRNA field. The company has a proven mRNA Medicines Platform and a next-generation lipid nanoparticle (LNP) technology that is designed to stimulate immune responses to cancers and infectious diseases.
Moreover, Providence has manufacturing and regulatory platforms that can produce mRNA-based vaccines and therapeutics ranging from personalized to pandemic scales. Providence has a pipeline of partnered and internal program in oncology, infectious diseases and animal health. The company also partners for target discovery with academic institutes and industry partners for co-development and LNP licensing.

RNA Technologies and Therapeutics Inc. (RNA T&T) is a privately held company headquartered in Montreal, Canada. It specializes in designing, optimizing, and small to medium-scale production (mg to g) of RNA, including nucleoside-modified messenger RNA, RNA, and LNP formulations, and developing mRNA-based technologies/therapeutics.

Rynd Biotech is building a quantitative rapid urine diagnostic platform using aptamer technology for sexually transmitted infections (STIs). We specialize in providing accurate, point-of-care testing solutions and discreet at-home testing.

Our innovative technology aims to redefine STI management by automating diagnosis and prescription delivery upon positive test results.

Solstar Pharma has developed an siRNA platform technology using proprietary modified nucleic acid chemistry. Our modified nucleotides enhance the stability and optimize the mRNA target activity of our siRNAs. We are harnessing the power of siRNA to inhibit pathogen replication such as in coronavirus disease or block the production of cancer-causing proteins.

For 25 years, TransBIOTech has been accelerating the preclinical development of new therapies by offering the expertise required for drug discovery: pharmacology, cellular and molecular biology, immunology, biochemistry, pharmacokinetics and toxicology.

Our scientists use cutting-edge methods and create tailor-made models to study your candidate RNA therapies and assess their efficacy and safety prior to the clinical development phases. Our status as a Centre Collégial de Transfert Technologique (CCTT) positions us as the ideal partner to drive innovation in biotechnology.